Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical rapamycin cream for facial angiofibromas in tuberous sclerosis complex
2019-000752-34Phase 2Completed
- Sponsor
- DSLP
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sirolimus in facial angiofibroma and tuberous sclerosis complex (TSC) (3 arms), sponsored by DSLP. Primary endpoint: Successful treatment rate by IGA at week 26. Started Oct 2019; status: completed.
02
Drugs
sirolimus
03
Conditions
facial angiofibromatuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on 2019-000752-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000752-34.